GLPG Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

69.40M

-8.08%

-0.130

-134.21%

71.08M

-5.2%

-1.210

-48.07%

70.58M

+8.11%

0.280

-117.5%

Estimates Revision

The market is revising Downward the revenue expectations for Galapagos NV (GLPG) for FY2025, with the revenue forecasts being adjusted by -0.02% over the past three months. During the same period, the stock price has changed by -2.67%.

Revenue Estimates for FY2025

Revise Downward

-0.02%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+12.65%

In Past 3 Month

Stock Price

Go Down

-2.67%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast GLPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLPG is 30.50 USD with a low forecast of 22.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

2 Sell

Hold

Current: 0.000

Low

22.00

Averages

30.50

High

40.00

Current: 0.000

Low

22.00

Averages

30.50

High

40.00

Bernstein

Market Perform

initiated

€27.90

2025-11-26

Reason

Bernstein

Price Target

€27.90

2025-11-26

initiated

Market Perform

Reason

Bernstein initiated coverage of Galapagos with a Market Perform rating and EUR 27.90 price target. The firm says the company has transformed itself from a biotech with a cell therapy pipeline into an investment company that seeks to build biotech businesses. Galapagos has undergone a "complete reset," the analyst tells investors in a research note.

RBC Capital

Sector Perform

maintain

$28 -> $32

2025-11-07

Reason

RBC Capital

Price Target

$28 -> $32

2025-11-07

maintain

Sector Perform

Reason

RBC Capital raised the firm's price target on Galapagos (GLPG) to $32 from $28 and keeps a Sector Perform rating on the shares. The firm is citing better than expected cost/interest structure, along with increased Gilead (GILD) amenability to recast Galapagos economics, the analyst tells investors in a research note.

RBC Capital

Brian Abrahams

Sector Perform

maintain

$27 -> $28

2025-10-22

Reason

RBC Capital

Brian Abrahams

Price Target

$27 -> $28

2025-10-22

maintain

Sector Perform

Reason

RBC Capital analyst Brian Abrahams raised the firm's price target on Galapagos (GLPG) to $28 from $27 and keeps a Sector Perform rating on the shares. The formal wind-down of the CAR-T program is not entirely surprising, but forces a re-think of how to appropriately value a company with a significant balance sheet and a biopharma-experienced leadership team but which is effectively a cash shell with unknown BD outcomes and some encumbrance from the Gilead (GILD) collaboration, the analyst tells investors in a research note.

Leerink

Market Perform -> Outperform

upgrade

$40

2025-10-21

Reason

Leerink

Price Target

$40

2025-10-21

upgrade

Market Perform -> Outperform

Reason

Leerink upgraded Galapagos to Outperform from Market Perform with a $40 price target.

Leerink

Faisal Khurshid

Market Perform -> Outperform

upgrade

$29 -> $40

2025-10-21

Reason

Leerink

Faisal Khurshid

Price Target

$29 -> $40

2025-10-21

upgrade

Market Perform -> Outperform

Reason

Leerink analyst Faisal Khurshid upgraded Galapagos to Outperform from Market Perform with a price target of $40, up from $29. The firm has "renewed confidence" in the company's plans to ease spending and pursue reasonable business development following the announcement that it would wind down its cell therapy business. In addition, Galapagos shares continue to trade at "deeply negative" enterprise value, the analyst tells investors in a research note. Leerink believes the company's new management has proven capable of "making tough but needed decisions." The firm sees the stock trading up towards Galapagos' cash balance as the market gains confidence in management.

Deutsche Bank

Hold

Sell

downgrade

€19

2025-08-05

Reason

Deutsche Bank

Price Target

€19

2025-08-05

downgrade

Hold

Sell

Reason

Deutsche Bank downgraded Galapagos to Sell from Hold with a EUR 19 price target.

Valuation Metrics

The current forward P/E ratio for Galapagos NV (GLPG.O) is -42.96, compared to its 5-year average forward P/E of -6.17. For a more detailed relative valuation and DCF analysis to assess Galapagos NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.17

Current PE

-42.96

Overvalued PE

92.90

Undervalued PE

-105.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.00

Current EV/EBITDA

5.71

Overvalued EV/EBITDA

17.58

Undervalued EV/EBITDA

4.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.92

Current PS

6.60

Overvalued PS

8.42

Undervalued PS

5.42

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GLPG News & Events

Events Timeline

No data

News

8.5

01-06Benzinga

Vistra Corp Acquires Cogentrix Energy for Approximately $4.7 Billion

9.5

01-06Benzinga

Microchip Technology Raises Q3 FY2026 Sales Guidance to $1.185 Billion

9.0

2025-12-18Globenewswire

Galapagos GLPG3667 Achieves Significant Clinical Benefit in Dermatomyositis Study

People Also Watch

Frequently Asked Questions

What is Galapagos NV (GLPG) stock price today?

The current price of GLPG is 33.11 USD — it has increased 0.36 % in the last trading day.

What is Galapagos NV (GLPG)'s business?

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.

What is the price predicton of GLPG Stock?

What is Galapagos NV (GLPG)'s revenue for the last quarter?

Galapagos NV revenue for the last quarter amounts to 71.16M USD, increased 18.90 % YoY.

What is Galapagos NV (GLPG)'s earnings per share (EPS) for the last quarter?

Galapagos NV. EPS for the last quarter amounts to -3.07 USD, increased 303.95 % YoY.

What changes have occurred in the market's expectations for Galapagos NV (GLPG)'s fundamentals?

How many employees does Galapagos NV (GLPG). have?

Galapagos NV (GLPG) has 704 emplpoyees as of January 10 2026.

What is Galapagos NV (GLPG) market cap?

Today GLPG has the market capitalization of 2.18B USD.